Rhotekin contributes to osteoblast differentiation and bone homeostasis by interacting with Chibby 1.
Wang Y., Shi L., Yang Y., Wang S., Chen M., Xie Y.
Animal Study, published in Cell Signal (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Cell Signal (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42000008
- DOI
- 10.1016/j.cellsig.2026.112542
Abstract (original English)
Rhotekin, an effector protein for Rho proteins, is implicated in tumorigenesis, yet its function in other biological processes remains largely unexplored. In the current study, we investigate the function of Rhotekin in osteoblast differentiation and bone homeostasis. Our data show that Rhotekin is expressed in bone and adipose tissue, with its levels increasing as mesenchymal progenitor cells differentiate toward both osteoblasts and adipocytes. When Rhotekin is overexpressed in progenitor cells, it facilitates osteogenic differentiation while inhibiting adipogenic differentiation, whereas knockdown of Rhotekin leads to opposite effects. Moreover, in vivo silencing of Rhotekin in bone marrow results in an increase in adipocytes and a decrease in osteoblasts, ultimately leading to a reduction in cancellous bone mass in mice. Further mechanistic investigations unveil that Rhotekin interacts with Chibby 1 (CBY1), an antagonistic regulator of β-catenin, and competes with β-catenin for binding to CBY1, thereby activating the canonical Wnt/β-catenin pathway. CBY1 is found to suppress osteoblast differentiation, an effect that is counteracted by overexpression of Rhotekin. Moreover, Rhotekin activates the focal adhesion kinase (FAK)/AKT signaling. Collectively, this study provides compelling evidence that Rhotekin interacts with CBY1, relieves its antagonistic effect on β-catenin, an
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.